AN2 Therapeutics, Inc. (ANTX)
ANTX moved a median of -0.14% 30 minutes after news, and 0.00% by the close. How ANTX actually reacts to news — the realized, point-in-time move the market made, measured across 307 labeled events over the last three years with zero look-ahead.
ANTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 31% | 290 |
| 30-min | -0.14% | 42% | 294 |
| 60-min | 0.00% | 44% | 307 |
| to close | 0.00% | 38% | 303 |
| Middle 50% of ANTX reactions | -1.28% to +1.33% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 307 |
Half of all AN2 Therapeutics, Inc. news events land between -1.28% and +1.33% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ANTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANTX's baseline. Nothing else.
Recent ANTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK | Press release | Business Wire | -4.50% | +2.45% | |
| AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) | Press release | Business Wire | -1.11% | -9.09% | |
| Form S-8 AN2 Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -1.29% | |
| AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting | Press release | Business Wire | +2.53% | -0.90% | |
| AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer | Press release | Business Wire | -0.34% | -3.27% | |
| AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights | Press release | Business Wire | +10.92% | +3.12% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +10.92% | +3.12% | |
| Form 8-K AN2 Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +10.92% | +3.12% | |
| Form 8-K AN2 Therapeutics, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +2.63% | |
| AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease | Press release | Business Wire | +1.41% | -2.34% | |
| Form 8-K AN2 Therapeutics, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -8.83% | |
| AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference | Press release | Business Wire | +0.22% | +6.30% | |
| AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights | Press release | Business Wire | +0.66% | -6.77% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.66% | -6.77% | |
| Form 8-K AN2 Therapeutics, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | -6.77% | |
| AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum | Press release | Business Wire | +0.22% | -2.83% | |
| Form ARS AN2 Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.25% | +7.27% | |
| Form DEF 14A AN2 Therapeutics, Inc. For: Apr 22 | SEC filing · Form DEF | SEC EDGAR | +0.25% | +7.27% | |
| Form DEFA14A AN2 Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.25% | +7.27% | |
| Form EFFECT AN2 Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +6.14% | |
| Form 8-K AN2 Therapeutics, Inc. For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -1.00% | |
| Form S-3 AN2 Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.67% | -1.00% | |
| AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease | Press release | Business Wire | -3.42% | -2.56% | |
| Form D AN2 Therapeutics, Inc. | SEC filing · Form D | SEC EDGAR | +3.00% | -1.37% | |
| Form 8-K AN2 Therapeutics, Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | -1.03% | |
| AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights | Press release | Business Wire | +0.62% | -4.74% | |
| Form 10-K AN2 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.62% | -4.74% | |
| Form 8-K AN2 Therapeutics, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +0.62% | -4.74% | |
| Form S-8 AN2 Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.62% | -4.74% | |
| Form 8-K AN2 Therapeutics, Inc. For: Mar 08 | SEC filing · Form 8-K | SEC EDGAR | +3.83% | +16.17% | |
| AN2 Therapeutics Announces $40 Million Private Placement Financing | Press release | Business Wire | +3.00% | +75.00% | |
| AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) | Press release | Business Wire | -0.91% | +21.82% | |
| AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference | Press release | Business Wire | +0.00% | -0.94% | |
| Form 8-K AN2 Therapeutics, Inc. For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease | Press release | Business Wire | +1.53% | -12.98% | |
| AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights | Press release | Business Wire | +0.00% | — | |
| Form 10-Q AN2 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form 8-K AN2 Therapeutics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) | Press release | Business Wire | +0.00% | +1.72% | |
| AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference | Press release | Business Wire | +0.00% | +1.79% | |
| AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease | Press release | Business Wire | — | — | |
| AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights | Press release | Business Wire | +0.47% | -0.94% | |
| Form 10-Q AN2 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.47% | -0.94% | |
| Form 8-K AN2 Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | -0.94% | |
| AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease | Press release | Business Wire | -0.89% | -0.87% | |
| AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole | Press release | Business Wire | -0.93% | -1.85% | |
| Form 8-K AN2 Therapeutics, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.90% | |
| Form 8-K AN2 Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.89% | |
| AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference | Press release | Business Wire | -0.89% | +7.08% | |
| Form 8-K AN2 Therapeutics, Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANTX section they belong to.
Where else ANTX is measured.
ANTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AN2 Therapeutics, Inc.'s median reaction calculated?
Every labeled ANTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 307 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of ANTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.